SFDA grants marketing authorization for 2 Saudi-developed AI-enabled medical software products

The Saudi Food and Drug Authority (SFDA) has officially granted marketing authorization to two locally developed, AI-enabled medical software products. The approval marks a significant milestone in the Kingdom’s ongoing efforts to integrate advanced artificial intelligence into its national healthcare infrastructure, specifically targeting the fields of dentistry and ophthalmology.

The two approved platforms, branded as 'Dental IQ' and 'SAARIA,' underwent a rigorous regulatory review process. According to the SFDA, this assessment included a comprehensive evaluation of technical documentation and clinical evidence to ensure that the software meets the necessary safety, performance, and effectiveness standards required for clinical use within the Saudi healthcare system.

The 'Dental IQ' software is designed to assist dental practitioners by utilizing deep learning algorithms to analyze X-ray imagery. The system is capable of identifying potential pathological findings, such as dental caries, periodontal disease, and various structural changes in teeth and supporting tissues, thereby aiding clinicians in improving diagnostic accuracy and treatment planning. Meanwhile, the 'SAARIA' software focuses on ophthalmology, employing AI technologies to analyze retinal fundus images to support the screening of diabetic patients for early detection of complications.

This authorization aligns with the broader goals of Saudi Vision 2030, which emphasizes the digitalization of the health sector to improve patient outcomes and operational efficiency. By fostering local innovation in medical software, the SFDA aims to reduce reliance on imported diagnostic tools while simultaneously enhancing the quality of care provided to patients across the Kingdom.